Neuronetics reports preliminary Q4 2025 revenue $41.8M, up 23% pro forma; positive operating cash flow

Neuronetics, Inc.

2025-FY EPS reported -$0.59 revenue$149,157,000

Q4 revenue $41.8M, 23% YoY pro forma growth; NeuroStar revenue $18.3M (+9% pro forma).
Full year 2025 revenue $149.2M, 15% pro forma growth; clinic revenue $87.0M (+28% pro forma).
Q4 operating cash flow positive $0.9M; total cash $34.1M at year-end.
49 NeuroStar systems shipped in Q4.
Final Q4 results to be released March 17, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.